Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

135 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-07-31

Study Completion Date

2007-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to see if pegfilgrastim (Neulasta) is safe and useful in supporting people through dose-dense chemotherapy, and to see if a long-acting red blood cell growth factor, darbepoetin alfa(Aranesp) can reduce the need for blood transfusion in chemotherapy recipients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and Ifosfamide

NCT00283621

Sarcoma

COMPLETED NA

Treatment for Patients Suffering From Anemia Due to Chemotherapy

NCT00120692

Breast Cancer Anemia

COMPLETED PHASE2

Evaluating Treatment of Anemia in Subjects With Non-Myeloid MalignanciesReceiving Multicycle Chemotherapy

NCT00111462

Anemia Non-Myeloid Malignancies Cancer

COMPLETED PHASE2

Immunogenicity Assessment of Peg-filgrastim vs. Neulasta® as Adjunct to Chemotherapy in Patients With Breast Cancer

NCT03511378

Breast Cancer

COMPLETED PHASE4

Anemia in Patients With a Non-Myeloid Malignancy

NCT00038064

Neoplasms Anemia

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* Patients will receive chemotherapy every 2 weeks for up to 8 cycles (spread out of approximately 16 weeks, total) of treatment. On the day of chemotherapy treatment patients may receive an injection of darbepoetin alfa in addition to chemotherapy if their red blood cell count is below normal levels.
* On the day after chemotherapy treatment, patients will receive an injection of pegfilgrastim. There is one pegfilgrastim shot given per treatment cycle, for a total of 8 injections. Once the patient has finished chemotherapy and the last of the pegfilgrastim shots, their participation in this trial will be complete.
* While on this study the following procedures will be performed: a physical exam will be done every 2 weeks, vital signs will be done every 2 weeks, and blood tests every 2 weeks.
* This study also involves a Quality of Life Questionnaire done at the beginning of study treatment, at 2 months, 4 months, 6 months, and 1 year after starting the study treatment.
* Patients will remain on this study unless they experience unacceptable side effects from any of the treatment drugs.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Stage I Breast Cancer Stage II Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Darbepoetin Alfa

Given day before chemotherapy of red blood cell count is below normal

Intervention Type DRUG

Pegfilgrastim

Given as an injection the day before chemotherapy for a total of 8 injections

Intervention Type DRUG

Paclitaxel

As part of standard adjuvant chemotherapy: Given every two weeks for 8 cycles

Intervention Type DRUG

Doxorubicin

As part of standard adjuvant chemotherapy: Given every two weeks for 8 cycles

Intervention Type DRUG

Cyclophosphamide

As part of standard adjuvant chemotherapy: Given every two weeks for 8 cycles

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Aranesp Neulasta

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically or cytologically confirmed breast cancer clinical stage I, II or III disease. Patients must be deemed of sufficient risk for tumor or recurrence
* Patients may receive the defined adjuvant chemotherapy treatment either following definitive breast surgery or prior to definitive breast surgery
* 18 years of age or older
* ECOG performance status 0 or 1
* ANC \> 1,500/uL
* Hemoglobin \> 9 g/dL
* Platelets \> 100,000/ul
* Total bilirubin less than or equal to ULN
* AST/ALT \< 1.5 x ULN
* Creatinine within normal institutional limits
* PT/PTT \< institutional upper limit of normal
* LVEF \> 50%

Exclusion Criteria

* Previous cytotoxic chemotherapy or therapeutic radiation therapy
* Pregnant or lactating women
* Receiving any other investigational agents
* Stage IV breast cancer
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to pegfilgrastim or darbepoetin
* Previous exposure to G-CSF or pegfilgrastim or to recombinant erythropoetin-related growth factors.
* On antibiotics within 72 hours of registration
* Patients with immune deficiency who are at increased risk of lethal infections when treated with marrow-suppressive therapy, or HIV-positive patients receiving anti-retroviral therapy
* Sickle cell disease
* Known positive antibody response to any erythropoietic agent
* Known hematologic diseases
* Known history of hyperviscosity syndrome
* Patients on lithium
* RBC transfusion within past 4 weeks

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No